Bio-Techne Corporation (TECH)
USD 50.73
(2.98%)
USD 50.73
(2.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 168.1 Million USD | -41.07% |
| 2023 | 285.26 Million USD | 4.86% |
| 2022 | 272.05 Million USD | 93.75% |
| 2021 | 140.41 Million USD | -38.76% |
| 2020 | 229.29 Million USD | 138.67% |
| 2019 | 96.07 Million USD | -23.36% |
| 2018 | 125.35 Million USD | 62.19% |
| 2017 | 77.28 Million USD | -26.03% |
| 2016 | 104.47 Million USD | -3.03% |
| 2015 | 107.73 Million USD | -2.9% |
| 2014 | 110.94 Million USD | -1.43% |
| 2013 | 112.56 Million USD | 0.2% |
| 2012 | 112.33 Million USD | 0.03% |
| 2011 | 112.3 Million USD | 2.3% |
| 2010 | 109.77 Million USD | 4.31% |
| 2009 | 105.24 Million USD | 1.63% |
| 2008 | 103.55 Million USD | 21.67% |
| 2007 | 85.11 Million USD | 16.03% |
| 2006 | 73.35 Million USD | 10.92% |
| 2005 | 66.13 Million USD | 24.95% |
| 2004 | 52.92 Million USD | 16.59% |
| 2003 | 45.39 Million USD | 67.33% |
| 2002 | 27.12 Million USD | -20.31% |
| 2001 | 34.04 Million USD | 28.07% |
| 2000 | 26.58 Million USD | 59.18% |
| 1999 | 16.7 Million USD | 9.87% |
| 1998 | 15.2 Million USD | 39.45% |
| 1997 | 10.9 Million USD | 26.74% |
| 1996 | 8.6 Million USD | 28.36% |
| 1995 | 6.7 Million USD | 31.37% |
| 1994 | 5.1 Million USD | 15.91% |
| 1993 | 4.4 Million USD | 120.0% |
| 1992 | 2 Million USD | 25.0% |
| 1991 | 1.6 Million USD | 60.0% |
| 1990 | 1 Million USD | 150.0% |
| 1989 | 400 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 27.46 Million USD | -46.14% |
| 2024 Q1 | 50.99 Million USD | -32.45% |
| 2024 Q3 | 49.05 Million USD | 78.62% |
| 2024 Q4 | 40.58 Million USD | -17.27% |
| 2024 FY | 168.1 Million USD | -41.07% |
| 2023 FY | 285.26 Million USD | 4.86% |
| 2023 Q1 | 89.55 Million USD | 45.56% |
| 2023 Q2 | 50 Million USD | -44.16% |
| 2023 Q4 | 75.48 Million USD | 7.5% |
| 2023 Q3 | 70.21 Million USD | 40.42% |
| 2022 Q3 | 60.73 Million USD | -24.24% |
| 2022 Q4 | 61.52 Million USD | 1.29% |
| 2022 FY | 272.05 Million USD | 93.75% |
| 2022 Q2 | 80.17 Million USD | 15.17% |
| 2022 Q1 | 69.61 Million USD | 365.34% |
| 2021 Q3 | 45.78 Million USD | -1.06% |
| 2021 Q4 | 14.96 Million USD | -67.32% |
| 2021 Q1 | 33.39 Million USD | -43.25% |
| 2021 Q2 | 46.27 Million USD | 38.57% |
| 2021 FY | 140.41 Million USD | -38.76% |
| 2020 Q4 | 58.84 Million USD | 61.53% |
| 2020 Q1 | 14.39 Million USD | -12.52% |
| 2020 Q2 | 119.62 Million USD | 730.82% |
| 2020 Q3 | 36.43 Million USD | -69.54% |
| 2020 FY | 229.29 Million USD | 138.67% |
| 2019 FY | 96.07 Million USD | -23.36% |
| 2019 Q1 | 17.4 Million USD | -57.45% |
| 2019 Q4 | 16.45 Million USD | -63.14% |
| 2019 Q3 | 44.65 Million USD | 154.35% |
| 2019 Q2 | 17.55 Million USD | 0.88% |
| 2018 Q1 | 15.86 Million USD | -44.94% |
| 2018 FY | 125.35 Million USD | 62.19% |
| 2018 Q4 | 40.9 Million USD | 107.22% |
| 2018 Q3 | 19.73 Million USD | -59.59% |
| 2018 Q2 | 48.84 Million USD | 207.93% |
| 2017 Q2 | 6.31 Million USD | -61.23% |
| 2017 Q3 | 21.38 Million USD | 238.81% |
| 2017 Q1 | 16.28 Million USD | -36.46% |
| 2017 FY | 77.28 Million USD | -26.03% |
| 2017 Q4 | 28.81 Million USD | 34.7% |
| 2016 Q1 | 22.7 Million USD | -13.76% |
| 2016 FY | 104.47 Million USD | -3.03% |
| 2016 Q2 | 25.85 Million USD | 13.85% |
| 2016 Q4 | 25.62 Million USD | -15.4% |
| 2016 Q3 | 30.29 Million USD | 17.18% |
| 2015 Q3 | 24.29 Million USD | -26.86% |
| 2015 FY | 107.73 Million USD | -2.9% |
| 2015 Q4 | 26.32 Million USD | 8.39% |
| 2015 Q2 | 33.2 Million USD | 38.91% |
| 2015 Q1 | 23.9 Million USD | -10.87% |
| 2014 Q1 | 27.42 Million USD | -3.46% |
| 2014 Q2 | 25.05 Million USD | -8.65% |
| 2014 FY | 110.94 Million USD | -1.43% |
| 2014 Q4 | 26.82 Million USD | -15.22% |
| 2014 Q3 | 31.64 Million USD | 26.29% |
| 2013 FY | 112.56 Million USD | 0.2% |
| 2013 Q4 | 28.41 Million USD | -14.21% |
| 2013 Q3 | 33.11 Million USD | 30.57% |
| 2013 Q2 | 25.36 Million USD | -1.18% |
| 2013 Q1 | 25.66 Million USD | -5.77% |
| 2012 Q1 | 27.52 Million USD | -2.86% |
| 2012 Q3 | 31.75 Million USD | 23.02% |
| 2012 Q2 | 25.81 Million USD | -6.21% |
| 2012 Q4 | 27.24 Million USD | -14.22% |
| 2012 FY | 112.33 Million USD | 0.03% |
| 2011 Q4 | 28.33 Million USD | -8.8% |
| 2011 FY | 112.3 Million USD | 2.3% |
| 2011 Q1 | 26.37 Million USD | 1.85% |
| 2011 Q2 | 26.53 Million USD | 0.61% |
| 2011 Q3 | 31.06 Million USD | 17.07% |
| 2010 Q1 | 26.77 Million USD | 5.46% |
| 2010 FY | 109.77 Million USD | 4.31% |
| 2010 Q4 | 25.89 Million USD | -20.05% |
| 2010 Q3 | 32.38 Million USD | 31.01% |
| 2010 Q2 | 24.72 Million USD | -7.66% |
| 2009 Q2 | 23.62 Million USD | -17.39% |
| 2009 Q3 | 27.64 Million USD | 17.01% |
| 2009 Q4 | 25.38 Million USD | -8.16% |
| 2009 FY | 105.24 Million USD | 1.63% |
| 2009 Q1 | 28.59 Million USD | 4.9% |
| 2008 FY | 103.55 Million USD | 21.67% |
| 2008 Q3 | 29.59 Million USD | 25.17% |
| 2008 Q1 | 23.07 Million USD | 0.65% |
| 2008 Q2 | 23.63 Million USD | 2.46% |
| 2008 Q4 | 27.25 Million USD | -7.88% |
| 2007 Q4 | 22.92 Million USD | -4.06% |
| 2007 FY | 85.11 Million USD | 16.03% |
| 2007 Q3 | 23.89 Million USD | 28.02% |
| 2007 Q2 | 18.66 Million USD | -4.93% |
| 2007 Q1 | 19.63 Million USD | 0.73% |
| 2006 Q2 | 16.51 Million USD | -2.86% |
| 2006 Q1 | 17 Million USD | -8.43% |
| 2006 FY | 73.35 Million USD | 10.92% |
| 2006 Q4 | 19.48 Million USD | -4.22% |
| 2006 Q3 | 20.34 Million USD | 23.21% |
| 2005 Q1 | 14.19 Million USD | 6.17% |
| 2005 FY | 66.13 Million USD | 24.95% |
| 2005 Q2 | 14.93 Million USD | 5.23% |
| 2005 Q4 | 18.56 Million USD | 0.69% |
| 2005 Q3 | 18.43 Million USD | 23.47% |
| 2004 Q1 | 12.57 Million USD | -0.82% |
| 2004 Q3 | 14.61 Million USD | 18.18% |
| 2004 Q4 | 13.36 Million USD | -8.56% |
| 2004 Q2 | 12.37 Million USD | -1.61% |
| 2004 FY | 52.92 Million USD | 16.59% |
| 2003 Q4 | 12.67 Million USD | 2.28% |
| 2003 Q3 | 12.39 Million USD | 25.42% |
| 2003 FY | 45.39 Million USD | 67.33% |
| 2003 Q1 | 10.44 Million USD | 3539.69% |
| 2003 Q2 | 9.88 Million USD | -5.4% |
| 2002 FY | 27.12 Million USD | -20.31% |
| 2002 Q1 | 8.42 Million USD | -10.33% |
| 2002 Q2 | 8.43 Million USD | 0.12% |
| 2002 Q3 | 10.57 Million USD | 25.36% |
| 2002 Q4 | -303.65 Thousand USD | -102.87% |
| 2001 FY | 34.04 Million USD | 28.07% |
| 2001 Q4 | 9.39 Million USD | -7.57% |
| 2001 Q3 | 10.16 Million USD | 45.57% |
| 2001 Q2 | 6.98 Million USD | -6.94% |
| 2001 Q1 | 7.5 Million USD | -11.95% |
| 2000 Q3 | 7.64 Million USD | 36.6% |
| 2000 Q1 | 4.8 Million USD | -5.88% |
| 2000 Q2 | 5.6 Million USD | 16.67% |
| 2000 FY | 26.58 Million USD | 59.18% |
| 2000 Q4 | 8.52 Million USD | 11.39% |
| 1999 Q4 | 5.1 Million USD | 13.33% |
| 1999 Q3 | 4.5 Million USD | 25.0% |
| 1999 FY | 16.7 Million USD | 9.87% |
| 1999 Q2 | 3.6 Million USD | 2.86% |
| 1999 Q1 | 3.5 Million USD | -27.08% |
| 1998 Q4 | 4.8 Million USD | 20.0% |
| 1998 Q3 | 4 Million USD | 29.03% |
| 1998 Q2 | 3.1 Million USD | -6.06% |
| 1998 Q1 | 3.3 Million USD | -5.71% |
| 1998 FY | 15.2 Million USD | 39.45% |
| 1997 Q1 | 2.2 Million USD | -15.38% |
| 1997 FY | 10.9 Million USD | 26.74% |
| 1997 Q2 | 2.3 Million USD | 4.55% |
| 1997 Q3 | 3 Million USD | 30.43% |
| 1997 Q4 | 3.5 Million USD | 16.67% |
| 1996 FY | 8.6 Million USD | 28.36% |
| 1996 Q4 | 2.6 Million USD | 4.0% |
| 1996 Q3 | 2.5 Million USD | 47.06% |
| 1996 Q1 | 1.8 Million USD | -14.29% |
| 1996 Q2 | 1.7 Million USD | -5.56% |
| 1995 Q1 | 1.4 Million USD | -17.65% |
| 1995 Q2 | 1.4 Million USD | 0.0% |
| 1995 Q3 | 1.8 Million USD | 28.57% |
| 1995 Q4 | 2.1 Million USD | 16.67% |
| 1995 FY | 6.7 Million USD | 31.37% |
| 1994 Q1 | 1.1 Million USD | -8.33% |
| 1994 FY | 5.1 Million USD | 15.91% |
| 1994 Q3 | 1.5 Million USD | 87.5% |
| 1994 Q4 | 1.7 Million USD | 13.33% |
| 1994 Q2 | 800 Thousand USD | -27.27% |
| 1993 FY | 4.4 Million USD | 120.0% |
| 1993 Q1 | 900 Thousand USD | -18.18% |
| 1993 Q2 | 1 Million USD | 11.11% |
| 1993 Q3 | 1.2 Million USD | 20.0% |
| 1993 Q4 | 1.2 Million USD | 0.0% |
| 1992 Q4 | 1.1 Million USD | 57.14% |
| 1992 Q3 | 700 Thousand USD | 133.33% |
| 1992 Q2 | 300 Thousand USD | 250.0% |
| 1992 FY | 2 Million USD | 25.0% |
| 1992 Q1 | -200 Thousand USD | -133.33% |
| 1991 Q2 | 300 Thousand USD | 50.0% |
| 1991 Q4 | 600 Thousand USD | 20.0% |
| 1991 Q1 | 200 Thousand USD | -50.0% |
| 1991 Q3 | 500 Thousand USD | 66.67% |
| 1991 FY | 1.6 Million USD | 60.0% |
| 1990 FY | 1 Million USD | 150.0% |
| 1990 Q4 | 400 Thousand USD | 33.33% |
| 1990 Q2 | 200 Thousand USD | 100.0% |
| 1990 Q3 | 300 Thousand USD | 50.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1989 FY | 400 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Caribou Biosciences, Inc. | -102.07 Million USD | 264.696% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 983.42% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 578.386% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 429.243% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 183.389% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 226.878% |
| Agenus Inc. | -245.76 Million USD | 168.402% |
| Fortress Biotech, Inc. | -60.63 Million USD | 377.232% |
| GlycoMimetics, Inc. | -36.89 Million USD | 555.576% |
| Novavax, Inc. | -545.06 Million USD | 130.841% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 209.878% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 18059.936% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 271.279% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 2614.66% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 423.746% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 138.185% |
| AlloVir, Inc. | -190.41 Million USD | 188.282% |
| Aptorum Group Limited | -2.82 Million USD | 6051.363% |
| Ardelyx, Inc. | -66.06 Million USD | 354.446% |
| Bicycle Therapeutics plc | -180.66 Million USD | 193.048% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 193.886% |
| Chimerix, Inc. | -82.09 Million USD | 304.769% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 476.889% |
| CRISPR Therapeutics AG | -153.61 Million USD | 209.436% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 617.485% |
| Precision BioSciences, Inc. | -61.31 Million USD | 374.148% |
| Dyadic International, Inc. | -6.79 Million USD | 2573.784% |
| Elevation Oncology, Inc. | -45.7 Million USD | 467.812% |
| Fortress Biotech, Inc. | -60.63 Million USD | 377.232% |
| GT Biopharma, Inc. | -7.59 Million USD | 2312.781% |
| Alkermes plc | 355.75 Million USD | 52.747% |
| Immix Biopharma, Inc. | -15.42 Million USD | 1189.748% |
| Innoviva, Inc. | 179.72 Million USD | 6.464% |
| IO Biotech, Inc. | -86.08 Million USD | 295.282% |
| Jaguar Health, Inc. | -41.3 Million USD | 507.034% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -222.324% |
| ContextLogic Inc. | -317 Million USD | 153.03% |
| AbCellera Biologics Inc. | -146.39 Million USD | 214.827% |
| Lantern Pharma Inc. | -15.96 Million USD | 1153.188% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 2077.473% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 181.893% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 144.992% |
| MEI Pharma, Inc. | 17.77 Million USD | -845.579% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 329.191% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 790.673% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 218.882% |
| NextCure, Inc. | -62.72 Million USD | 368.012% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 306.062% |
| ChromaDex Corporation | -4.93 Million USD | 3504.313% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 248.817% |
| Incyte Corporation | 597.59 Million USD | 71.87% |
| Opthea Limited | -220.24 Million USD | 176.327% |
| MiMedx Group, Inc. | 67.43 Million USD | -149.27% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 385.007% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 355.615% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 428.593% |
| Vaxcyte, Inc. | -402.26 Million USD | 141.79% |
| PDS Biotechnology Corporation | -42.94 Million USD | 491.468% |
| Pharming Group N.V. | -10.54 Million USD | 1693.714% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 784.941% |
| Onconetix, Inc. | -37.4 Million USD | 549.362% |
| Acelyrin, Inc. | -381.64 Million USD | 144.048% |
| PureTech Health plc | -65.69 Million USD | 355.879% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 327.815% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 179.213% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 1006.417% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 790.673% |
| ESSA Pharma Inc. | -26.58 Million USD | 732.393% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 769.981% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 1783.407% |
| Seer, Inc. | -86.27 Million USD | 294.843% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 165.2% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 550.201% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 717.171% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 1340362.735% |
| Summit Therapeutics Inc. | -614.92 Million USD | 127.337% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 592.962% |
| Senti Biosciences, Inc. | -92.91 Million USD | 280.916% |
| ImmuCell Corporation | -5.77 Million USD | 3011.112% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 202.146% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 388.379% |
| Precigen, Inc. | -95.9 Million USD | 275.285% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 408.892% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 525.809% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 260.56% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 370.027% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 1386.006% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 129.346% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 350.922% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 672.526% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 690.837% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 928.471% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 392.29% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 204.46% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 4785.201% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 169.649% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -135.408% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 442.233% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 1789.88% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 168.448% |
| Aptose Biosciences Inc. | -51.2 Million USD | 428.285% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 271.016% |
| Soligenix, Inc. | -6.14 Million USD | 2837.541% |
| Century Therapeutics, Inc. | -136.67 Million USD | 222.998% |
| Kura Oncology, Inc. | -152.63 Million USD | 210.138% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 288.42% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 1695.227% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -29628.368% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 29643.937% |
| Autolus Therapeutics plc | -208.38 Million USD | 180.671% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 333.81% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 337.453% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 875.821% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 174.63% |
| GRI Bio, Inc. | -13.03 Million USD | 1389.445% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 4165.832% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 235.477% |
| IGM Biosciences, Inc. | -246.41 Million USD | 168.22% |
| INmune Bio, Inc. | -30 Million USD | 660.201% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 252.05% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 498.412% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1153.18% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 1164.294% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 381.654% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 266.166% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 160.88% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 170.664% |
| Verastem, Inc. | -87.36 Million USD | 292.412% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 410.226% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 204.196% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 244.101% |
| Histogen Inc. | -10.62 Million USD | 1682.761% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 1276.649% |
| Surrozen, Inc. | -43.04 Million USD | 490.56% |
| Organovo Holdings, Inc. | -14.67 Million USD | 1245.832% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 3404.581% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 421.185% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 765.42% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 724.044% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 2111.527% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 211.265% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 443.59% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 665.534% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 1713.647% |
| Apollomics, Inc. | -172.6 Million USD | 197.395% |
| Amarin Corporation plc | -59.11 Million USD | 384.384% |
| Mesoblast Limited | -87.95 Million USD | 291.124% |
| Turnstone Biologics Corp. | -55.2 Million USD | 404.538% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 214.387% |
| Synaptogenix, Inc. | -6.03 Million USD | 2883.885% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 1137.173% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 315.464% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 3608.425% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 2100.727% |
| Exelixis, Inc. | 207.76 Million USD | 19.089% |
| Better Therapeutics, Inc. | -39.76 Million USD | 522.799% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 216.782% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 131.8% |
| NLS Pharmaceutics AG | -12.17 Million USD | 1481.076% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 2256.66% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 646.701% |
| Gritstone bio, Inc. | -138.49 Million USD | 221.384% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 360.769% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 4302.678% |
| Avid Bioservices, Inc. | -140.75 Million USD | 219.433% |
| Insmed Incorporated | -749.56 Million USD | 122.427% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 1206.718% |
| MediWound Ltd. | -6.71 Million USD | 2603.052% |
| OmniAb, Inc. | -50.61 Million USD | 432.099% |
| Alector, Inc. | -130.39 Million USD | 228.924% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 247.818% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 424.233% |
| Zai Lab Limited | -334.62 Million USD | 150.238% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 151.887% |
| Aura Biosciences, Inc. | -76.4 Million USD | 320.01% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 171.646% |
| Immunic, Inc. | -93.61 Million USD | 279.576% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 223.704% |
| Veracyte, Inc. | -74.4 Million USD | 325.935% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 2290.136% |
| FibroGen, Inc. | -284.23 Million USD | 159.144% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 740.839% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 2500.852% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 992.623% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 59.476% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 845.311% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -241.184% |
| TG Therapeutics, Inc. | 12.67 Million USD | -1226.586% |
| Galecto, Inc. | -38.34 Million USD | 538.356% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 991.047% |
| Fortrea Holdings Inc. | -3.4 Million USD | 5044.265% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 232.738% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 1065.51% |
| XBiotech Inc. | -24.55 Million USD | 784.55% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 360.769% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 368.196% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 270.793% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 884.548% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 404.577% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 127.711% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 346.29% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 295362.936% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 174.206% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 854.934% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 176.512% |
| NexImmune, Inc. | -32.34 Million USD | 619.735% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 3279.848% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 1296.827% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 95.748% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 794.046% |
| Scopus BioPharma Inc. | -11.6 Million USD | 1547.954% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 243.928% |
| Ainos, Inc. | -13.77 Million USD | 1320.757% |
| Pluri Inc. | -20.88 Million USD | 904.792% |
| Prothena Corporation plc | -147.02 Million USD | 214.335% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 247.628% |
| Celularity Inc. | -196.29 Million USD | 185.639% |
| Rallybio Corporation | -74.56 Million USD | 325.451% |
| Cue Biopharma, Inc. | -50.73 Million USD | 431.352% |
| MeiraGTx Holdings plc | -84.02 Million USD | 300.061% |
| Omeros Corporation | -117.81 Million USD | 242.688% |
| Humacyte, Inc. | -110.77 Million USD | 251.752% |
| Immunocore Holdings plc | -55.28 Million USD | 404.059% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 1034.748% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 833.091% |
| Blueprint Medicines Corporation | -506.98 Million USD | 133.158% |
| CalciMedica, Inc. | -34.35 Million USD | 589.289% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 348.4% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 201.397% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 159.348% |
| Pulmatrix, Inc. | -14.12 Million USD | 1290.461% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 577.639% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 303.423% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 134.935% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 260.297% |
| Cytokinetics, Incorporated | -526.24 Million USD | 131.944% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 566.117% |
| Nutriband Inc. | -5.48 Million USD | 3164.638% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 515.896% |
| Vor Biopharma Inc. | -117.86 Million USD | 242.627% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 96.135% |
| Evogene Ltd. | -23.87 Million USD | 803.987% |
| ProKidney Corp. | -35.46 Million USD | 573.962% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 240.365% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 2242.723% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 126.136% |
| CorMedix Inc. | -46.33 Million USD | 462.77% |
| BioLineRx Ltd. | -60.61 Million USD | 377.337% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 265.224% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 509.353% |
| Atai Life Sciences N.V. | -40.22 Million USD | 517.922% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 308.437% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 322.594% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 157.533% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 703.046% |
| MediciNova, Inc. | -8.57 Million USD | 2061.205% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 236.364% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 2106.784% |
| GeoVax Labs, Inc. | -25.96 Million USD | 747.385% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 170.267% |
| Biomea Fusion, Inc. | -117.25 Million USD | 243.367% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 126.828% |
| Mereo BioPharma Group plc | -29.46 Million USD | 670.505% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 209.756% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 180.295% |
| Absci Corporation | -110.56 Million USD | 252.04% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 657.562% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 266.71% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 171.25% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -1093.588% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 187.118% |
| Allakos Inc. | -185.7 Million USD | 190.525% |
| Imunon, Inc. | -19.51 Million USD | 961.415% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 272.708% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -58.38% |
| BioAtla, Inc. | -123.46 Million USD | 236.159% |
| NLS Pharmaceutics AG | -12.17 Million USD | 1481.076% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 1145.559% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 151.367% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 554.965% |
| XOMA Corporation | -40.83 Million USD | 511.709% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 265.019% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 241.845% |
| aTyr Pharma, Inc. | -50.38 Million USD | 433.614% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 291.728% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 210.771% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 170.711% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 578.673% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 2177.438% |
| Akari Therapeutics, Plc | -10 Million USD | 1779.706% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 249791.794% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 40.302% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 2622.244% |
| UroGen Pharma Ltd. | -102.24 Million USD | 264.416% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 257.412% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 2261.515% |
| Orgenesis Inc. | -55.36 Million USD | 403.652% |
| Entera Bio Ltd. | -8.88 Million USD | 1991.158% |
| GH Research PLC | -35.58 Million USD | 572.378% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 906.646% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 317.224% |
| Xencor, Inc. | -126.08 Million USD | 233.325% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 4564.108% |
| Replimune Group, Inc. | -215.79 Million USD | 177.901% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 890.467% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -6600.08% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 2622.244% |
| Portage Biotech Inc. | -75.33 Million USD | 323.131% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 2106.784% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 273.923% |
| OncoCyte Corporation | -27.78 Million USD | 705.108% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 1352.906% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 1611.529% |
| Purple Biotech Ltd. | -19.88 Million USD | 945.599% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 2494.999% |
| scPharmaceuticals Inc. | -54.81 Million USD | 406.705% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 1060.263% |
| HilleVax, Inc. | -123.56 Million USD | 236.045% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 1763.253% |
| Tharimmune, Inc. | -9.31 Million USD | 1903.877% |
| Genprex, Inc. | -30.86 Million USD | 644.726% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 171.254% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 658.6% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 9533.502% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 3274.179% |
| OKYO Pharma Limited | -16.82 Thousand USD | 999210.871% |
| Savara Inc. | -54.69 Million USD | 407.333% |
| Curis, Inc. | -47.41 Million USD | 454.555% |
| Daré Bioscience, Inc. | -30.16 Million USD | 657.352% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 1188.404% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 3118.585% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 663.827% |
| BeiGene, Ltd. | -881.7 Million USD | 119.066% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 889.448% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 138.524% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 312.912% |
| Erasca, Inc. | -125.04 Million USD | 234.439% |
| bluebird bio, Inc. | -211.91 Million USD | 179.327% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 3461.766% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -0.274% |
| DBV Technologies S.A. | -72.72 Million USD | 331.148% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 3461.766% |
| Moderna, Inc. | -4.71 Billion USD | 103.566% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 518.619% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 3052.318% |
| Molecular Templates, Inc. | -8.12 Million USD | 2169.239% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 378.375% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 250.904% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 224.198% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 450.811% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 218.862% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 187.368% |
| MacroGenics, Inc. | -9.05 Million USD | 1955.873% |
| RenovoRx, Inc. | -10.23 Million USD | 1742.934% |
| Adicet Bio, Inc. | -142.65 Million USD | 217.838% |
| Prime Medicine, Inc. | -198.13 Million USD | 184.845% |
| Aditxt, Inc. | -32.38 Million USD | 619.15% |
| Adagene Inc. | -18.94 Million USD | 987.268% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2399.116% |
| Quantum-Si incorporated | -95.96 Million USD | 275.182% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 241.23% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 1253.16% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -27.035% |
| SciSparc Ltd. | -5.12 Million USD | 3382.019% |
| Vericel Corporation | -3.18 Million USD | 5382.998% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 139891.608% |
| Minerva Neurosciences, Inc. | -30 Million USD | 660.25% |
| Generation Bio Co. | -126.61 Million USD | 232.772% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 330.625% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 303.907% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 164.128% |
| Invivyd, Inc. | -198.64 Million USD | 184.627% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 149.157% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 2035.228% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -637.109% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 1802.502% |
| 2seventy bio, Inc. | -217.57 Million USD | 177.265% |
| ADMA Biologics, Inc. | -28.23 Million USD | 695.294% |
| Clene Inc. | -49.5 Million USD | 439.579% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 854.255% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 440.059% |
| GeoVax Labs, Inc. | -25.96 Million USD | 747.385% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 151.241% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 616.564% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -639.899% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 270.161% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 324.878% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 204.54% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 127.331% |
| Evaxion Biotech A/S | -22.12 Million USD | 859.797% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 308.216% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 184.024% |
| Trevena, Inc. | -40.28 Million USD | 517.248% |
| Surrozen, Inc. | -43.04 Million USD | 490.56% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 343.158% |
| Cingulate Inc. | -23.53 Million USD | 814.278% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 2532.075% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 521.739% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 2280.16% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 286.349% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 374.296% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 382.515% |
| Clearmind Medicine Inc. | -11.95 Million USD | 1506.144% |
| Kronos Bio, Inc. | -112.67 Million USD | 249.197% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 342.937% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 6628244.924% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 295.71% |
| Statera Biopharma, Inc. | -174.4 Million USD | 196.386% |
| ImmunityBio, Inc. | -583.19 Million USD | 128.825% |
| Korro Bio, Inc. | -81.17 Million USD | 307.097% |
| Kineta, Inc. | -14.09 Million USD | 1292.319% |
| BioVie Inc. | -32.12 Million USD | 623.357% |
| Codexis, Inc. | -76.24 Million USD | 320.494% |
| Celularity Inc. | -196.29 Million USD | 185.639% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 178.36% |
| Celcuity Inc. | -63.77 Million USD | 363.574% |
| Virax Biolabs Group Limited | -6.73 Million USD | 2596.533% |
| Cibus, Inc. | -267.62 Million USD | 162.813% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 516.865% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 569.423% |
| IN8bio, Inc. | -30 Million USD | 660.219% |
| Kodiak Sciences Inc. | -260.49 Million USD | 164.534% |
| Annexon, Inc. | -134.23 Million USD | 225.23% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 243.477% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 374.556% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 632.922% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 145.894% |
| Eyenovia, Inc. | -27.26 Million USD | 716.648% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -678.588% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 31521.495% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 320.021% |
| Arcellx, Inc. | -70.69 Million USD | 337.806% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 505.649% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 225.624% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 659.66% |
| Moolec Science SA | -51.78 Million USD | 424.597% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 420.989% |
| Geron Corporation | -184.12 Million USD | 191.298% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 500.498% |
| Royalty Pharma plc | 1.13 Billion USD | 85.187% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 223.647% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 1990.561% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 891.334% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 197.923% |
| Humacyte, Inc. | -110.77 Million USD | 251.752% |
| Structure Therapeutics Inc. | -89.62 Million USD | 287.575% |
| 89bio, Inc. | -142.18 Million USD | 218.226% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 343.772% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 1719.977% |
| Genelux Corporation | -28.29 Million USD | 694.074% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 678.376% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 194.911% |
| Notable Labs, Ltd. | -11.26 Million USD | 1592.409% |
| Liquidia Corporation | -78.5 Million USD | 314.141% |
| Mustang Bio, Inc. | -51.6 Million USD | 425.772% |
| Immunovant, Inc. | -259.33 Million USD | 164.821% |
| Quantum-Si incorporated | -95.96 Million USD | 275.182% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 330.758% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 967.37% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 275.128% |
| Acasti Pharma Inc. | -12.85 Million USD | 1407.905% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 848.535% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1153.18% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 192.166% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 4008.04% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 1448.075% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 670.021% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 531.171% |
| PepGen Inc. | -78.62 Million USD | 313.803% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 664.698% |
| United Therapeutics Corporation | 984.8 Million USD | 82.93% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 855.189% |
| Solid Biosciences Inc. | -96.01 Million USD | 275.082% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 3608.425% |
| Immuneering Corporation | -53.47 Million USD | 414.382% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 3404.581% |
| Silo Pharma, Inc. | -3.7 Million USD | 4642.54% |
| Belite Bio, Inc | -31.63 Million USD | 631.44% |
| XOMA Corporation | -40.83 Million USD | 511.709% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 409.215% |
| Bionomics Limited | -15.49 Billion USD | 101.085% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 300.161% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 676.551% |
| uniQure N.V. | -308.47 Million USD | 154.495% |
| Cassava Sciences, Inc. | -97.21 Million USD | 272.917% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2399.116% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 236.195% |
| Forte Biosciences, Inc. | -31.47 Million USD | 634.074% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 2149.635% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 678.316% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 31521.495% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 740.839% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 1119.745% |
| Altimmune, Inc. | -88.44 Million USD | 290.063% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 210.899% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 676.551% |
| Compugen Ltd. | -18.75 Million USD | 996.369% |
| Peak Bio, Inc. | -1259.26 USD | 13349606.853% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 465.057% |
| Benitec Biopharma Inc. | -21.75 Million USD | 872.861% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 149.619% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 302.648% |
| Zura Bio Limited | -60.36 Million USD | 378.504% |
| PolyPid Ltd. | -23.86 Million USD | 804.4% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 1168.555% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 302.648% |
| Instil Bio, Inc. | -156.08 Million USD | 207.7% |
| argenx SE | -295.05 Million USD | 156.975% |
| Immunome, Inc. | -106.8 Million USD | 257.393% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 495.597% |
| Verona Pharma plc | -54.36 Million USD | 409.193% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 268.245% |
| Shattuck Labs, Inc. | -87.29 Million USD | 292.565% |
| CervoMed Inc. | -2.17 Million USD | 7840.093% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 234.861% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 1362.429% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 485.96% |
| Moolec Science SA | -51.78 Million USD | 424.597% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 972269.933% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 224.414% |
| AnaptysBio, Inc. | -163.61 Million USD | 202.742% |
| Design Therapeutics, Inc. | -66.86 Million USD | 351.421% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 306.482% |
| NeurAxis, Inc. | -14.62 Million USD | 1249.304% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 543.76% |
| Lumos Pharma, Inc. | -34.03 Million USD | 593.933% |
| Achilles Therapeutics plc | -69.66 Million USD | 341.305% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 268.245% |
| 180 Life Sciences Corp. | -19.93 Million USD | 943.261% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -5487.13% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 6628244.924% |
| Nutriband Inc. | -5.48 Million USD | 3164.638% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 266.941% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 445.845% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 318.06% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 594.863% |
| MoonLake Immunotherapeutics | -36 Million USD | 566.864% |
| Palisade Bio, Inc. | -12.3 Million USD | 1466.707% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 499.072% |
| Beam Therapeutics Inc. | -132.52 Million USD | 226.846% |
| Neurogene Inc. | -36.31 Million USD | 562.882% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 202.87% |
| AEON Biopharma, Inc. | -52.55 Million USD | 419.859% |
| Sesen Bio, Inc. | -19.88 Million USD | 945.428% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 334.836% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 1443.347% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 137.858% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 250.678% |
| Athira Pharma, Inc. | -117.67 Million USD | 242.859% |
| Vaccinex, Inc. | -20.25 Million USD | 930.107% |
| HCW Biologics Inc. | -24.99 Million USD | 772.574% |
| XOMA Corporation | -40.83 Million USD | 511.709% |
| Nektar Therapeutics | -276.05 Million USD | 160.895% |
| Arvinas, Inc. | -367.3 Million USD | 145.768% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 249791.794% |
| Merus N.V. | -154.93 Million USD | 208.498% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 272.543% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 635.622% |
| Rezolute, Inc. | -68.45 Million USD | 345.556% |
| Clene Inc. | -49.5 Million USD | 439.579% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 1189.93% |
| BeyondSpring Inc. | -21.02 Million USD | 899.51% |
| Synlogic, Inc. | -57.28 Million USD | 393.469% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 1512.528% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 1652.79% |
| Peak Bio, Inc. | -1259.26 USD | 13349606.853% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 549.864% |
| Krystal Biotech, Inc. | 10.93 Million USD | -1437.733% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 217.475% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 151.708% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 3739.452% |
| MannKind Corporation | -11.93 Million USD | 1508.15% |
| Ikena Oncology, Inc. | -68.16 Million USD | 346.611% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 899.929% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 280.888% |
| Gossamer Bio, Inc. | -179.81 Million USD | 193.487% |
| CohBar, Inc. | -11.96 Million USD | 1505.311% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 751.873% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 657.562% |
| Legend Biotech Corporation | -518.25 Million USD | 132.437% |
| Mural Oncology plc | -207.44 Million USD | 181.035% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 235.443% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 1019.123% |
| Disc Medicine, Inc. | -76.42 Million USD | 319.949% |
| Champions Oncology, Inc. | -7.27 Million USD | 2410.404% |
| REGENXBIO Inc. | -263.49 Million USD | 163.798% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 1683.943% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 453.868% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 542.574% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 267.831% |
| Vaxart, Inc. | -82.46 Million USD | 303.85% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -50266.577% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 547.772% |
| Cellectis S.A. | -101.05 Million USD | 266.343% |
| Longeveron Inc. | -21.41 Million USD | 885.06% |
| Repare Therapeutics Inc. | -93.79 Million USD | 279.224% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 131.364% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 336.205% |
| Revolution Medicines, Inc. | -436.36 Million USD | 138.524% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 2658.286% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 645.37% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 342.46% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 359.694% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 1813.434% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 95.356% |
| Denali Therapeutics Inc. | -145.22 Million USD | 215.756% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 139891.608% |
| Veru Inc. | -93.15 Million USD | 280.462% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 721.943% |
| Cingulate Inc. | -23.53 Million USD | 814.278% |
| Passage Bio, Inc. | -102.06 Million USD | 264.709% |
| Context Therapeutics Inc. | -23.96 Million USD | 801.484% |
| Exicure, Inc. | -16.91 Million USD | 1093.881% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 188.984% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 545.146% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 2683.32% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 191.026% |
| Nuvalent, Inc. | -126.21 Million USD | 233.185% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 1698.616% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 293.493% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 650.37% |
| OmniAb, Inc. | -50.61 Million USD | 432.099% |
| Anew Medical, Inc. | 1.34 Million USD | -12388.068% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 1147.71% |
| Lipocine Inc. | -16.35 Million USD | 1128.034% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 353.193% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 364.005% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 498.412% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 450.46% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 947.688% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 131.045% |
| Ocugen, Inc. | -63.07 Million USD | 366.503% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 275.6% |
| Q32 Bio Inc. | -112.96 Million USD | 248.817% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 1077.809% |
| Alumis Inc. Common Stock | -154.99 Million USD | 208.46% |
| Equillium, Inc. | -13.33 Million USD | 1360.63% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 378.476% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 2204.512% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 991.746% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 384.528% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 246.782% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 1014.71% |
| Dominari Holdings Inc. | -22.88 Million USD | 834.66% |
| Edesa Biotech, Inc. | -8.37 Million USD | 2107.364% |
| vTv Therapeutics Inc. | -20.25 Million USD | 930.148% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 147.745% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -30.463% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 237.981% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 543.093% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 249.238% |
| Nkarta, Inc. | -117.5 Million USD | 243.067% |
| BioCardia, Inc. | -11.57 Million USD | 1552.813% |
| Iterum Therapeutics plc | -38.37 Million USD | 538.104% |